Emergex and Saudi Arabia’s Vaccine Industrial Company (VIC) have Signed MoU to Advance First-of-its-Kind Infectious Disease Solutions
This Collaboration supports the Kingdom of Saudi Arabia’s Vision 2030 to boost the biopharma sector through increasing local and regional production as well as accessibility of healthcare solutions.
- This Collaboration supports the Kingdom of Saudi Arabia’s Vision 2030 to boost the biopharma sector through increasing local and regional production as well as accessibility of healthcare solutions.
- ABINGDON, United Kingdom, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’) a clinical-stage biotechnology company on the forefront of combatting global infectious diseases, has announced that the Company has signed a Memorandum of Understanding with the Vaccine Industrial Company (VIC) for a Collaboration Agreement advancing Emergex’s novel T cell-priming immune set-point candidates against designated infectious diseases.
- This agreement is a testament to Emergex’s promising technology as a vital contributor to game changing healthcare solutions around the world.
- Emergex’s novel approach offers a safe, easy-to-administer and highly effective solution, alternative to mainstream methods, to protect against infectious diseases.